Theratechnologies inc.

Theratechnologies inc.

July 31, 2008 09:00 ET

Theratechnologies Presents at Both BMO and Canaccord Adams Conferences and Comments on Strategic Review

MONTREAL, CANADA--(Marketwire - July 31, 2008) - Theratechnologies (TSX:TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will present corporate overviews at both the BMO Capital Markets Focus on Healthcare Conference and the 28th Annual Canaccord Adams Global Growth Conference.

The BMO presentation will take place on August 5, at 1:45 p.m., at the Millennium Broadway Hotel in New York City and the Canaccord Adams presentation, on August 14, at 11:30 a.m., at the InterContinental in Boston.

Strategic Review

Theratechnologies also confirms that its strategic review process is still active and ongoing and that the Company is in advanced discussions with parties at this time. The positive results from the confirmatory Phase 3 clinical trial that were disclosed in mid-June 2008, have been very beneficial in moving the strategic review forward. As disclosed earlier, there is no specific timetable set for completion; however, the Independent Committee of the Board of Directors is diligently working towards completing the process as soon as possible. As previously stated, the Company will advise its shareholders of any material developments in due course.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to, information regarding the impact of the results of the confirmatory Phase 3 clinical trial on moving the strategic review forward and the timing regarding the completion of the process. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms or variations of them and the use of the future or conditional tense as well as similar expressions denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to the risk that the Company does not complete any transaction in connection with the strategic review.

Although the forward-looking information contained herein is based upon what the Company believes are reasonable assumptions, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information.

Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences or effects on the Company, its business, its financial condition or its results of operation. Investors are referred to the Company's public filings available at In particular, further details and descriptions of these and other factors are disclosed in the "Risk and Uncertainties" section of the Company's Annual Information Form, dated January 29, 2008, for the year ended November 30, 2007. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Contact Information